ArticleInvestigative ophthalmology & visual science2025
Dual VEGF-Targeting Strategy Via AAV2-Delivered sFLT-1 and shVEGF for Retinal Neovascularization Therapy.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- cGAS-STING Pathway Mediates Retinal Pigmental Epithelial Dysfunction in Diabetic Retinopathy.Diabetes · 2026Article
- A Potential Gut-Retina Axis in Retinopathy of Prematurity: Emerging Perspectives on Microbiome-Mediated Modulation of the IGF-1-VEGF Pathway.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Retinal neovascular diseases, often associated with elevated vascular endothelial growth factor (VEGF) levels, are major causes of blindness. Current therapies lack sustained efficacy and safety. This study aimed to evaluate the effectiveness of an adeno-associated virus 2 (AAV2)-based gene therapy vector carrying soluble fms-like tyrosine kinase-1 (sFLT-1) and short hairpin RNA targeting VEGF (shVEGF) in treating retinal neovascularization. Methods: P12 mice were divided into six groups: normal group, control group, AAV2-EGFP group, AAV2-sFLT group, AAV2-shVEGF group, and AAV2-sFLT-shVEGF group. AAV2 vectors encoding sFLT-1 alone, shVEGF alone, or a combination of both sFLT-1 and shVEGF were administered to oxygen-induced retinopathy (OIR) mice via intravitreal injection. Fundus photography and fluorescein fundus angiography (FFA) were used to evaluate retinal vascular morphology and density. Hematoxylin and eosin (H&E) staining was used to observe the growth characteristics of retinal neovascularization. The expression levels of angiogenic factors, inflammatory mediators, and blood-retina barrier-associated markers were assessed using immunofluorescence and quantitative PCR (qPCR). Electroretinography (ERG) was performed to evaluate retinal function. Results: All three gene therapy groups effectively suppressed pathological neovascularization in OIR mice, although their therapeutic outcomes showed subtle differences. The AAV2-shVEGF group demonstrated the strongest efficacy in promoting the regression of the central non-perfusion area. The AAV2-sFLT-shVEGF group was more effective in suppressing neovascular growth and inflammatory infiltration. All three groups exhibited comparable effects in reducing angiogenic factor expression and enhancing blood-retina barrier-related markers. Notably, only the AAV2-sFLT-shVEGF group showed a pronounced ability to restore retinal function. Conclusions: Dual inhibition with AAV2-sFLT-shVEGF offers a promising therapeutic approach for retinal neovascular diseases, demonstrating efficacy in reducing neovascularization and improving retinal health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.